Znachenie molekulyarnykh markerov pri vybore neoad\"yuvantnoy khimioterapii mestno-rasprostranennogo raka molochnoy zhelezy
- Authors: Semiglazova T.Y.1, Semiglazov V.V1, Filatova L.V1, Krivorot'ko P.V1, Klimenko V.V1, Ivanov V.G1, Novikov S.M1, Gershanovich M.L1, Imyanitov E.N1, Semiglazov V.F1
-
Affiliations:
- Issue: No 17 (2013)
- Pages: 57-64
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/282527
- ID: 282527
Cite item
Abstract
Full Text
About the authors
T. Yu Semiglazova
Email: tsemiglazova@mail.ru
V. V Semiglazov
L. V Filatova
P. V Krivorot'ko
V. V Klimenko
V. G Ivanov
S. M Novikov
M. L Gershanovich
E. N Imyanitov
V. F Semiglazov
References
- Мерабишвили В.М. Эпидемиология и выживаемость больных раком молочной железы // Вопр. онкологии 2013. Т. 59. № 3. C. 314-19.
- Имянитов Е.Н. Наследственный рак молочной железы // Практическая онкология 2010. Т. 11. № 4. С. 258-64.
- Имянитов Е.Н., Хансон К.П. Молекулярная онкология: клинические аспекты. СПб., 2007. 211 с.
- Cheang MCU, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009;101:736-50.
- Семиглазов В.Ф. Новые подходы к лечению рака молочной железы // Вопр. онкологии 2013. Т. 59. № 3. С. 288-91.
- Семиглазов В.Ф., Манихас А.Г., Семиглазова Т.Ю., Бессонов А.А., Семиглазов В.В. Неоадъювантная системная терапия рака молочной железы. Руководство для врачей. СПб., 2012. 112 с.
- Семиглазов В.Ф., Семиглазов В.В., Манихас А.Г. Рак молочной железы. Химиотерапия и таргетная терапия. М., 2012. 360 с.
- Kong X, Moran MS, Zhang N, Haffty B, Yang Q. Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer 2011; 47:2084-90.
- Esserman LJ, Berry DA, DeMichele A, et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL-CALGB 150007/150012, ACRIN 6657. J Clin Oncol 2012;30:3242-49.
- Cortazar P, Zhang L, Untch M, et al. Metaanalysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC). Cancer Res 2012;72(Suppl. P1):14-20.
- Von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012;30: 1796-804.
- Miller ID, Payne S, Ogston KN. A new gistological grading system to assess response of breast cancer to primary chemotherapy. Int J Oncol 2002;20(4):791-96.
- Rouzier R, Perou CM, Symmans W, et al.Breast cancer molecular subtypes respond differently to preoperatory chemotherapy. Clin Cancer Res 2005;11:5678-85.
- Kamath K, Wilson L, Cabral F, Jordan M. BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem 2005;280(13):12902-907.
- Seve P, Dumontet C, Isaac S, et al. Class III B-tubulin expression in tumor cells predicts response and outcome in patients with nonsmall cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005;4(12):2001-07.
- Ferrandina G, Zannoni G, Martinelli E, et al. Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res 2006; 12(9):2774-79.
- Urano N, Fujiwara Y, Doki Y, et al. Clinical significance of class III betatubulin expression and its predictive value for resistance to docetaxelbased chemotherapy in gastric cancer. Int J Oncol 2006;28(2):375-81.
- Burkhart C, Kavallaris M, Horwitz S. The role of /З-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta 2001; 1471(2):1-9.
- Evans W, Relling M. Pharmacogenomics: translation functional genomics into rational therapeutics. Science 1999;286:487-91.
- Knoop A, Knudsen H, Balslev E, et al. Danish Breast Cancer Cooperative Group. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005;23(30): 7483-90.
- Tanner M, Hollmen M, Junttila T, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005;16:273-78.
- Hannemann J, Kristel P, van Tinteren H, et al. Molecular subtypes of breast cancer and amplification of topoisomerase II: predictive role in dose intensive adjuvant chemotherapy. Br J Cancer 2006;95:1334-41.
- Brase J, Schmidt M, Fischbach T, et al. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction. Clin Cancer Res 2010;16(8):2391-401.
- Oakman C, Moretti E, Galardi F, et al. The role of topoisomerase II alpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients. Cancer Treat Rev 2009; 35(8):662-67.
- De Jong M, Nolte I, Meerman G, et al. Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J Med Genet 2002;39:225-42.
- Byrski T, Gronwald J, Huzarski T, et al. Pathologic complete response rates in young women with BRCA1 -positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010;28(3):375-79.
- Chappuis P, Goffin J, Wong N, et al. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet 2002;39:608-10.
- Schott S, Sohn C, Schneeweiss A, et al. Preoperative Systemic Treatment in BRCA-Positive Breast Cancer Patients: Case Report and Review of the Literature. Breast Care 2011;6:395-98.